公开(公告)号：US20240287182A1

公开(公告)日：2024-08-29

申请号：US18402031

申请日：2024-01-02

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Christoph MARKERT ,  Raymond D. MENG ,  Merlind MUECKE ,  Shiraj SEN ,  Volker TEICHGRAEBER ,  Volker Andreas WIEBKING ,  Edward Namserk CHA ,  Christopher Roland COTTER ,  Michelle Yuri DORAL

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/04

CPC classification number: C07K16/2818 ,  A61P35/04 ,  C07K16/2803 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/76

Abstract: This invention relates to methods and compositions for use in treating cancer in a subject. For example, the invention relates to methods and compositions for use in treating esophageal cancer or colorectal cancer (CRC) (e.g., metastatic CRC (e.g., microsatellite instability (MSI) high (MSI-H) metastatic CRC)) in a subject by administering to the subject an anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) antagonist antibody (e.g., tiragolumab) and a PD-1 axis binding antagonist (e.g., atezolizumab); methods and compositions for use in treating metastatic CRC (e.g., MSI-H metastatic CRC) in a subject by administering to the subject an anti-TIGIT antagonist antibody (e.g., tiragolumab), a PD-1 axis binding antagonist (e.g., atezolizumab), and an anti-VEGF antibody (e.g., bevacizumab); methods and compositions for use in treating melanoma in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1) and lymphocyte activation gene-3 (LAG3), optionally with an anti-TIGIT antagonist antibody (e.g., tiragolumab); and methods and compositions for use in treating a CD20-positive cell proliferative disorder (e.g., non-Hodgkin's lymphoma (NHL); e.g., relapsed or refractory NHL) in a subject by administering to the subject a bispecific antibody targeting CD20 and CD3 (mosunetuzumab) and an anti-TIGIT antagonist antibody (e.g., tiragolumab), optionally with a PD-1 axis binding antagonist (e.g., atezolizumab).

公开(公告)号：US20240327519A1

公开(公告)日：2024-10-03

申请号：US18424297

申请日：2024-01-26

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Henry KAO ,  Christoph MARKERT ,  Christine MCINTYRE ,  Raymond D. MENG ,  Merlind MUECKE ,  Volker TEICHGRAEBER ,  Laura CODARRI DEAK

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/22

CPC classification number: C07K16/2818 ,  C07K16/22 ,  C07K16/2803 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/90

Abstract: This invention relates to methods and compositions for use in treating cancer in a subject by administering to the subject a bispecific antibody targeting programmed cell death protein 1 (PD-1) and lymphocyte activation gene-3 (LAG3).